ClinicalTrials.gg
Sign In

Drug

Anti-PD-1/Anti-VEGF-A Bispecific Antibody CR-001 clinical trials

studies test it
3
open now
3
in phase 3
0
first study started
2026

Keep track of what changes. Save the Anti-PD-1/Anti-VEGF-A Bispecific Antibody CR-001 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.

Watch these studies

How studies write it

Studies that test it under each name

Combined with it in one product

SKB264+SKB118
2
SKB118+SKB264
1

By phase

A phase 1/2 study counts in both.

Phase 1
1
Phase 2
3

Who runs them

Industry 3 · Other 0

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (3)

Often tested with

Tested in the same studies.

Sacituzumab tirumotecan (3)

Studies

Open first, then newest update. How each study uses Anti-PD-1/Anti-VEGF-A Bispecific Antibody CR-001 is read from its arms, and is right about nine times in ten.

Testing it · 3

Given in every arm · 1 — Anti-PD-1/Anti-VEGF-A Bispecific Antibody CR-001 is usual care beside what is tested